Therachon Raises $60 Million Mezzanine Financing

09.08.2018 14:31

Related tags

Lab

Therachon AG, a Basel-based clinical-stage biotechnology company focused on rare diseases, today announced it has completed a $60 million mezzanine financing led by Novo Holdings.

The financing led by Novo Holdings was joined by new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed by Tekla Capital Management LLC. Existing investors Versant Ventures, OrbiMed, Bpifrance and Inserm Transfert Initiative also participated.

Therachon plans to use the proceeds to advance the company’s lead pipeline candidate TA-46, a novel protein therapeutic for achondroplasia, the most common form of disproportionate short stature in humans, as well as to support the expansion of its rare disease pipeline. TA-46 is being developed as a weekly subcutaneous therapy for children and adolescents living with achondroplasia.

Therachon is currently conducting a Phase 1 randomized, placebo-controlled, double-blind trial to evaluate the safety, tolerability and pharmacokinetics of single and multiple increasing doses of TA-46 in healthy volunteers. Therachon has also recently started a natural history study called the ‘Dreambird study,’ that will prospectively assess the burden of complications of achondroplasia in approximately 200 children across multiple sites in Europe, Canada and the United States and will enable the start of treatment studies in children with achondroplasia in 2019.

In conjunction with this financing, Jørgen Søberg Petersen M.D., Ph.D., DMSc, MBA, venture partner at Novo Holdings, and Timothy Anderson, director, Cowen Healthcare Investments, have been appointed members of Therachon’s Board of Directors.

(Press release)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Principal

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS

In order to provide the best quality for you, our system uses "cookies", which are stored on your device. Cookies are necessary to identify what information (job advertisement, questionnaire, etc) you have already seen. IP address is used for the same purposes as described above.

When creating a profile, applying to the newsletter, job subscriptions and etc, you agree that the data, which you have entered, will be stored and processed in the system in order to provide services, which you have applied for.

We do NOT sell your personal data to any 3rd party services.

You must be 18 or older years old to use our services. If you are underage, you must have a permission to use our services from your parent or guardian. It is necessary in order to store and process your data.

By continuing to use our services, you agree with the these terms. You can withdraw your agreement at any time, by deleting cookies from your device and by sending request for deleting your data to the administrator.